import { Patient } from "./types"

export const defaultPatients: Patient[] = [
    {
        slug: "john-doe",
        name: "John Doe",
        email: "johndoe@gmail.com",
        phone: "1234567890",
        status: "Deceased",
        dob: "01/01/1970",
        complaint: "Lung",
        imageUrl: "https://images.unsplash.com/photo-1494790108377-be9c29b29330?ixlib=rb-1.2.1&ixid=eyJhcHBfaWQiOjEyMDd9&auto=format&fit=facearea&facepad=4&w=256&h=256&q=6",    
    },
    {
        slug: "arnav-jain",
        name: "Arnav Jain",
        email: "arnavjain@gmail.com",
        phone: "1234567890",
        status: "Recovered",
        dob: "01/01/1970",
        complaint: "Breast",
        imageUrl: 'https://images.unsplash.com/photo-1570295999919-56ceb5ecca61?ixlib=rb-1.2.1&ixid=eyJhcHBfaWQiOjEyMDd9&auto=format&fit=facearea&facepad=4&w=256&h=256&q=60',
    },
    {
        slug: "joseph-cowles",
        name: "Joseph Cowles",
        email: "josephcowles@gmail.com",
        phone: "1234567890",
        status: "Undiagnosed",
        dob: "01/01/1970",
        complaint: "Lung",
        imageUrl: "https://images.unsplash.com/photo-1520813792240-56fc4a3765a7?ixlib=rb-1.2.1&ixid=eyJhcHBfaWQiOjEyMDd9&auto=format&fit=facearea&facepad=4&w=256&h=256&q=60",
    },
    {
        slug: "daniel-gorge",
        name: "Daniel Gorge",
        email: "danielgorge@gmail.com",
        phone: "1234567890",
        status: "Diagnosed",
        dob: "01/01/1970",
        complaint: "Breast",
        imageUrl: "https://images.unsplash.com/photo-1498551172505-8ee7ad69f235?ixlib=rb-1.2.1&ixid=eyJhcHBfaWQiOjEyMDd9&auto=format&fit=facearea&facepad=4&w=256&h=256&q=60",
    },
    {
        slug: "ahad-jawaid",
        name: "Ahad Jawaid",
        email: "ahadjawaid@gmail.com",
        phone: "1234567890",
        status: "Deceased",
        dob: "01/01/1970",
        complaint: "Lung",
        imageUrl: "https://images.unsplash.com/photo-1532417344469-368f9ae6d187?ixlib=rb-1.2.1&ixid=eyJhcHBfaWQiOjEyMDd9&auto=format&fit=facearea&facepad=4&w=256&h=256&q=60",
    }
]

export const patientTrialRequestData = {
    "patient": "The patient is a 60-year-old pre-menopausal woman presenting with a history of grade-3 locally advanced, triple-negative breast cancer on her left side. Despite neoadjuvant chemotherapy and subsequent mastectomy, the cancer has recurred, indicating progressive disease. Her current ECOG score is 1, signifying she is active but limited in strenuous physical activity. \\n\\nThe breast tumor is triple-negative as denoted by ER negativity (IHC<1%), PR negativity (IHC<1%), and HER2 negativity (IHC-/+ or IHC++ but FISH/CISH negative). The invasive tumor measures 4 cm with one objectively measurable lesion via RECIST 1.1 standard. She has no prior treatment experience with PD-1/PD-L1 antibody, CTLA-4 antibody, or anti-vascular targeted therapy. \\n\\nRecent blood reports show Hemoglobin of 95 g/L, Neutrophil count of 2.5×109/L, Platelet count of 120×109/L. Biochemical tests results reveal Total Bilirubin of 1.2×ULN, Alanine aminotransferase and Aspartate aminotransferase both at 1.5×ULN, and Serum creatinine of 1.3 ULN with a creatinine clearance of 70mL/min.\\n\\nShe has a history of smoking but no family history of breast cancer. The patient reports no known autoimmune diseases, serious infections, interstitial lung disease, or non-infectious pneumonia, or other harmful medical conditions. There have been no major surgical treatments or open biopsies conducted within the past 4 weeks.",
    "metadata": {
        "key1": "value1",
        "key2": "value2"
    }
}

export const cachedPatientTrialResponse = {
    "status": "success",
    "data": {
        "result": [
            {
                "patient_match_result": {
                    "reasoning": "The clinical trial in question is specifically designed for patients with HR-positive/HER2-negative advanced breast cancer. The patient in question, however, has triple-negative breast cancer, as indicated by ER negativity, PR negativity, and HER2 negativity. This means that the patient's cancer does not express the hormone receptors (estrogen and progesterone) or the HER2 receptor, which are the targets of the therapies being tested in the clinical trial.\n\nFurthermore, the trial's inclusion criteria specify that patients must have \"Histologically confirmed HR + / HER2- invasive breast cancer\". This again does not match the patient's diagnosis of triple-negative breast cancer.\n\nThe patient does meet some of the other inclusion criteria, such as being female, being within the age range, having measurable disease according to RECIST v1.1, having adequate bone marrow function, liver function, and kidney function, and having an ECOG score ≤ 2. However, the mismatch in the type of breast cancer makes the trial irrelevant for this patient.\n\nThe patient also does not meet any of the exclusion criteria, but again, the key issue is the mismatch in the type of breast cancer.\n\n",
                    "answer": "No"
                },
                "metadata": {
                    "Brief Summary": "This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.",
                    "Brief Title": "Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)",
                    "Conditions": "Breast Cancer, Metastatic Cancer",
                    "Eligibility": "Eligibility Criteria:\nHealthy Volunteers: False\nSex: FEMALE\nMinimum Age: 18 Years\nMaximum Age: 75 Years\nStandard Ages: ['ADULT', 'OLDER_ADULT']\nInclusion Criteria:  * Females ≥18 years and ≤ 75 years old; * Histologically confirmed HR + / HER2-\ninvasive breast cancer (specific definition: immunohistochemical detection of ER\\> 10% tumor cell\npositive is defined as ER positive, PR\\> 10% tumor cell positive is defined as PR positive, ER and /\nor PR Positive is defined as HR positive; HER2 0-1 + or HER2 is ++ but negative followed by FISH\ndetection, no amplification, defined as HER2 negative); * Subtype of similarity network fusion-2\n(SNF-2) confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan\nUniversity Affiliated Cancer Hospital * Locally advanced breast cancer (incapable of radical local\ntreatment) or recurrent metastatic breast cancer; * Measurable disease according to Response\nEvaluation Criteria in Solid Tumors v1.1 (RECIST v1.1); or unmeasurable lytic or mixed (osteolytic +\nosteoblastic) bone lesions in the absence of measurable lesions; * Has adequate bone marrow\nfunction: absolute neutrophil count \\> 1.5x10ˆ9 /L; platelet count \\> 75x10ˆ9 /L, hemoglobin \\>\n9g/dL; * Patients had received no previous chemotherapy or targeted therapy for metastatic disease *\nHas adequate liver function and kidney function: serum creatinine * ECOG score ≤ 2 and life\nexpectancy ≥ 3 months; * Participants voluntarily joined the study, has signed informed consent\nbefore any trial related activities are conducted, has good compliance and has agreed to follow-up.\nExclusion Criteria:  * Treatment with chemotherapy, radiotherapy, immunotherapy or surgery\n(outpatient clinic surgery excluded) for metastatic disease    * Symptomatic, untreated, or actively\nprogressing CNS metastases(glucocorticoids or mannitol needed to control symptoms);   * Significant\ncardiovascular disease(including congestive heart failure, angina pectoris, myocardial infarction or\nventricular arrhythmia in the last 6 months);   * is pregnant or breast feeding;   * Malignant\ntumors in the past five years (except cured skin basal cell carcinoma and cervical carcinoma in\nsitu).   * History of autoimmune disease   * Positive test for human immunodeficiency virus   *\nActive hepatitis B or hepatitis C   * Uncontrolled pleural effusion and ascites   * Thyroid\ndysfunction.",
                    "Interventions Description": "PD-L1 antibody, CDK4/6 inhibitor, Albumin bound paclitaxel, Fulvestrant, aromatase inhibitor",
                    "NCT ID": "NCT05205200",
                    "Official Title": "Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer"
                }
            },
            {
                "patient_match_result": {
                    "reasoning": "The clinical trial in question is a phase II study evaluating the efficacy and safety of maintenance treatment with eribulin mesylate following standard adjuvant chemotherapy in triple negative breast cancer patients. The patient in question is a 60-year-old pre-menopausal woman with a history of grade-3 locally advanced, triple-negative breast cancer. \n\nThe patient's cancer is triple-negative, which matches the condition targeted by the clinical trial. The patient's ECOG score is 1, which is within the eligibility criteria of the trial (ECOG PS: 0-1). The patient has not received any treatment with PD-1/PD-L1 antibody, CTLA-4 antibody, or anti-vascular targeted therapy, which is not a contraindication for the trial. \n\nHowever, there are several points of concern that may exclude the patient from the trial. Firstly, the patient's cancer has recurred despite neoadjuvant chemotherapy and mastectomy, indicating progressive disease. The trial is designed for patients who have undergone radical or breast conserving surgery with no evidence of metastasis. The patient's recurrent cancer may be considered as a form of metastasis, which could exclude her from the trial.\n\nSecondly, the patient's recent blood reports show a Hemoglobin level of 95 g/L, which is just at the lower limit of the trial's eligibility criteria (HB≥90g/L). Her Neutrophil count is 2.5×109/L, which is above the trial's minimum requirement (ANC ≥1.5×109/L). However, her Platelet count is 120×109/L, which is just above the trial's minimum requirement (PLT≥100×109/L). These borderline results may put the patient at risk of not meeting the trial's eligibility criteria in the future.\n\nThirdly, the patient's biochemical test results reveal a Total Bilirubin of 1.2×ULN, Alanine aminotransferase and Aspartate aminotransferase both at 1.5×ULN, and Serum creatinine of 1.3 ULN with a creatinine clearance of 70mL/min. These results are within the trial's eligibility criteria, but the elevated levels of Bilirubin, Alanine aminotransferase, Aspartate aminotransferase, and Serum creatinine may indicate potential liver and kidney issues that could affect the patient's ability to tolerate the trial treatment.\n\nLastly, the patient has a history of smoking, which is not mentioned in the trial's exclusion criteria, but could potentially affect her overall health and ability to tolerate the trial treatment.\n\nIn conclusion, while the patient's condition matches the target condition of the trial, her recurrent cancer, borderline blood test results, potential liver and kidney issues, and history of smoking may exclude her from the trial or put her at risk during the trial. Therefore, it would be prudent to discuss these concerns with the patient before considering her for the trial.\n\n",
                    "answer": "No"
                },
                "metadata": {
                    "Brief Summary": "This clinical trial is a multicenter, randomized, open-label, phase-II study to evaluate the efficacy and safety of maintenance treatment with eribulin mesylate following standard adjuvant chemotherapy in triple negative breast cancer patients.",
                    "Brief Title": "Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients",
                    "Conditions": "Triple Negative Breast Cancer",
                    "Eligibility": "Eligibility Criteria:\nHealthy Volunteers: False\nSex: FEMALE\nMinimum Age: 18 Years\nStandard Ages: ['ADULT', 'OLDER_ADULT']\nInclusion Criteria:  * The patient volunteers and signs an informed consent form; * Age ≥18 years\nold, female; * The patient was diagnosed as triple-negative breast cancer by histopathology (ER\nnegative (IHC ER positive percentage \\<1%), PR negative (IHC PR positive percentage \\<1%), HER2\nnegative (IHC-/+ or IHC++ but FISH/CISH- )), and there is no evidence of metastasis; * Patients\nunderwent radical or breast conserving surgery combined with sentinel lymph node biopsy for primary\nbreast cancer. Margins free of disease and ductal carcinoma in-situ (DCIS) are required. Lobular\ncarcinoma is not considered a positive margin. * For patients who have previously received\nneoadjuvant therapy for triple-negative breast cancer containing anthracyclines and taxanes, the\npostoperative efficacy evaluation did not reach pathological complete remission (non-PCR), that is,\nthe primary breast and/or metastatic regional lymph nodes still have histological evidence of\nmalignant tumors other than carcinoma in situ; * For patients who have not received neoadjuvant\ntherapy for triple-negative breast cancer, ≥1 ipsilateral axillary lymph nodes have pathological\ntumor involvement after surgery. Or the patient's postoperative lymph nodes are negative, but at\nleast meet one of the following conditions:    1. Primary invasive tumor size\\> 2cm in pathology;\n2. Ki-67 index of untreated breast tissue\\>30%;   3. The comprehensive score is at least 8 points\n(Elston and Ellis 1991) according to the improved Bloom-Richardson grading system (also known as the\nNottingham scale), which belongs to the 3rd level; * Physical condition ECOG PS: 0-1; * Previously\nreceived adjuvant chemotherapy consisting of a minimum of 6 courses with anthracyclines combined\ntaxanes; * Time window between end of adjuvant chemotherapy and study randomization must be less\nthan 8 weeks. In patients receiving adjuvant radiotherapy, time window allowed between last session\nand randomisation is 4 weeks; * Laboratory tests meet the following criteria:    1. Bone marrow\nfunction: absolute count of blood neutrophils (ANC) ≥1.5×109/L; platelet (PLT)≥100×109/L; hemoglobin\n(HB)≥90g/L;   2. Liver function: serum total bilirubin (STB), combined bilirubin (CB) ≤ upper limit\nof normal (ULN) \\*1.5; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ULN\\*2.5;\n3. Renal function: serum creatinine (Cr) ≤ ULN; endogenous creatinine clearance (Ccr) ≥ 60 ml / min\n(calculated using the Cockcroft-Gault formula).  Exclusion Criteria:  * Patients with metastatic\nbreast cancer (including contralateral axillary lymph nodes), inflammatory carcinomas; * Previous\nbreast cancer history (except for ipsilateral DCIS that only received local treatment ≥5 years ago),\nmalignant tumors of other histological origins (except for non-melanoma skin cancer or cervical\ncarcinoma in situ) unless the patient's tumor had been completely alleviated and had not received\ntreatment for at least 5 years before the enrollment date; * Major surgery within 4 weeks prior to\nenrollment, or surgical wounds have not healed; * Embolization and bleeding occurred within 4 weeks\nbefore enrollment; * Severe cardiovascular disease, including hypertension (BP≥160/95mmHg)\nuncontrolled by medical treatment, unstable angina, history of myocardial infarction in the past 6\nmonths, congestive heart failure\\>NYHA II, severe heart rhythm Abnormalities and pericardial\neffusions; * Severe infection requires intravenous antibiotic, antifungal or antiviral treatment; *\nSuffering from mental illness, poor compliance; * Researchers believe that it is not suitable for\ninclusion.",
                    "Interventions Description": "Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.",
                    "NCT ID": "NCT04502680",
                    "Official Title": "A Multicenter, Randomized, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Maintenance Treatment With Eribulin Mesylate Following Standard Adjuvant Chemotherapy in Triple Negative Breast Cancer Patients"
                }
            },
            {
                "patient_match_result": {
                    "reasoning": "The patient's case and the clinical trial both involve triple-negative breast cancer, which is a good starting point for considering the trial's relevance. The patient's age, 60, falls within the trial's age range of 18-70 years. The patient's ECOG score of 1 also matches the trial's requirement. The patient's tumor is triple-negative, which is a requirement for the trial, and the patient has not received any of the treatments (PD-1/PD-L1 antibody, CTLA-4 antibody, or anti-vascular targeted therapy) that might exclude her from the trial.\n\nHowever, there are several points of concern. The trial is for patients with stage IIA-IIIIC triple-negative breast cancer, but the patient's report does not specify her stage. The trial also requires that the patient's cancer be non-metastatic and surgically treated, but the patient's cancer has recurred after mastectomy, indicating progressive disease. This could potentially exclude her from the trial.\n\nThe patient's blood reports and biochemical test results seem to fall within the trial's requirements for adequate hematological and end-organ function. However, the patient's serum creatinine is slightly above the trial's limit of 1ULN, which could be a point of concern.\n\nThe patient's history of smoking and lack of family history of breast cancer do not seem to be relevant to the trial's inclusion or exclusion criteria. The patient does not have any of the medical conditions listed in the trial's exclusion criteria.\n\nIn conclusion, while there are several points of alignment between the patient's case and the trial, there are also several potential points of concern, particularly the patient's progressive disease and slightly elevated serum creatinine. These factors would need to be discussed with the trial's investigators to determine whether the patient could be eligible for the trial.\n\n",
                    "answer": "No"
                },
                "metadata": {
                    "Brief Summary": "This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.",
                    "Brief Title": "Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients.",
                    "Conditions": "Breast Cancer, Triple Negative Breast Cancer",
                    "Eligibility": "Eligibility Criteria:\nHealthy Volunteers: False\nSex: FEMALE\nMinimum Age: 18 Years\nMaximum Age: 70 Years\nStandard Ages: ['ADULT', 'OLDER_ADULT']\nInclusion Criteria:  * Women aged 18-70 years old; * Eastern Oncology Collaborative Group (ECOG)\nphysical status score: 0 or 1; * Histological results recorded as TNBC (negative HER2, ER, and PgR\nstatus) and BLIS subtype according to the classification of FUSCC; * Have stage IIA-IIIIC triple-\nnegative breast cancer with non-metastatic surgically treated: pT1-3N1-3M0; * Adequate hematological\nand end-organ function as defined by the following laboratory test results, which need to be\ncompleted within 28 days prior to the first study treatment: absolute neutrophil count (ANC) ≥ 1500\ncells/μL (no G-CSF support therapy within 2 weeks prior to day 1 of course 1); Platelet count ≥\n75×109/L (no platelet transfusion within 2 weeks before day 1 of course 1); hemoglobin ≥ 9.0 g/dL\n(no RBC transfusion within 2 weeks before day 1 of course 1); AST, ALT, and alkaline phosphatase ≤ 3\n× upper limit of normal (ULN) serum total bilirubin ≤ 1.0 × ULN; serum creatinine ≤ 1ULN and with an\nendogenous creatinine clearance rate of \\>50 ml/min (Cockcroft-Gault formula); * The surgical\nincision had fully healed prior to the commencement of the study; * Female participants of\nreproductive potential are required to use a medically accepted form of contraception during the\ncourse of the study treatment and for at least three months following the last administration of the\ninvestigational drug; * Sign the Informed Consent Form (ICF). The patient is judged by the\ninvestigator to have the ability to comply with the provisions of the protocol.  Exclusion Criteria:\n* Has received neoadjuvant therapy (including chemotherapy, targeted therapy, and radiotherapy) *\nHas bilateral breast cancer; * Has a previous history of additional malignancy, with the exception\nof adequately treated basal cell carcinoma and cervical carcinoma in situ. * Has metastatic (Stage\n4) breast cancer; * Has any \\>T4 lesion (UICC1987) (with skin involvement, mass adhesion and\nfixation, and inflammatory breast cancer); * Has severe organ dysfunction (cardiopulmonary liver and\nkidney) insufficiency, left ventricular ejection fraction (LVEF) \\< 50% (a cardiac ultrasound);\nsevere cardio cerebral vascular disease within the 6 months previous to randomization (such as\nunstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\\>150/90mmgh,\nmyocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control;\npatients with severe hypertension; * Is pregnant, breastfeeding women, or women of childbearing age\nwho cannot practice effective contraceptives; * Patients participating in other clinical trials at\nthe same time; * Has known allergy to taxane and excipients. * Has severe or uncontrolled infection;\n* Has a history of psychotropic substance abuse and was unable to abandon drug habits or those with\na history of mental disorders; * the researchers judged patients to be unsuitable for the study.",
                    "Interventions Description": "BP102 (anti VEGFR), ddEC-P",
                    "NCT ID": "NCT05909332",
                    "Official Title": "A Randomized, Open-label Phase III Clinical Trial Comparing Antivascular Therapy Combined With Standard Chemotherapy and Standard Chemotherapy in Adjuvant Therapy for Patients With Triple-Negative Breast Cancer, Basal-like Immunosuppressed Subtype."
                }
            },
            {
                "patient_match_result": {
                    "reasoning": "The clinical trial in question is a phase II study of Camrelizumab plus Apatinib and Chemotherapy as neoadjuvant therapy for Triple Negative Breast Cancer (TNBC). The patient in question is a 60-year-old pre-menopausal woman with a history of grade-3 locally advanced, triple-negative breast cancer. \n\nThe patient's cancer is triple-negative, which matches the condition targeted by the clinical trial. The patient's ECOG score is 1, which is within the eligibility criteria of the trial (ECOG Performance Status of 0-1). The patient has at least one measurable lesion according to RECIST 1.1, which is also a requirement for the trial. The patient has not received any prior treatment with PD-1/PD-L1 antibody, CTLA-4 antibody, or anti-vascular targeted therapy, which aligns with the exclusion criteria of the trial. \n\nHowever, the patient's cancer has recurred after neoadjuvant chemotherapy and mastectomy, indicating progressive disease. This could potentially be a point of concern as the trial excludes patients who have received any anti-tumor therapy within the past 12 months. \n\nThe patient's blood reports and biochemical test results seem to indicate adequate hematologic and organ function, which is a requirement for the trial. The patient does not have any known autoimmune diseases, serious infections, interstitial lung disease, or non-infectious pneumonia, which are all exclusion criteria for the trial. \n\nThe patient has a history of smoking but no family history of breast cancer. The trial does not specify any exclusion criteria related to smoking or family history of breast cancer. \n\nIn conclusion, the patient seems to meet most of the eligibility criteria for the trial. However, the fact that the patient's cancer has recurred after neoadjuvant chemotherapy and mastectomy could potentially be a point of concern. It would be important to discuss this with the trial investigators to determine whether the patient would still be eligible for the trial.\n\n",
                    "answer": "Yes"
                },
                "metadata": {
                    "Brief Summary": "The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).",
                    "Brief Title": "Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)",
                    "Conditions": "Triple Negative Breast Cancer",
                    "Eligibility": "Eligibility Criteria:\nHealthy Volunteers: False\nSex: FEMALE\nMinimum Age: 18 Years\nMaximum Age: 75 Years\nStandard Ages: ['ADULT', 'OLDER_ADULT']\nInclusion Criteria:  * Newly diagnosed breast cancer. * 18-75 Years, female. * Early or locally\nadvanced, histologically documented TNBC (absence of HER2, ER, and PR expression). * Tumor stage:\nII-III. * ECOG Performance Status of 0-1. * life expectancy is not less than 3 months. * at least\none measurable lesion according to RECIST 1.1. * Adequate hematologic and organ function. * Must be\nwilling to use an adequate method of contraception for the course of the study.  Exclusion Criteria:\n* Stage Ⅳ (metastatic) breast cancer or bilateral breast cancer. * Inflammatory breast cancer. * Has\nreceived prior any anti-tumor therapy within the past 12 months prior to signing informed consent,\nincluding chemotherapy, targeted therapy, radiation therapy, immunotherapy, biotherapy and TAE. *\nHas received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed\ndeath-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory\nT-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 \\[CTLA-4\\], and/or anti-VEGFR\nagent. * Has a history of invasive malignancy ≤5 years prior to signing informed consent except for\nadequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. * Major\nsurgical procedure within 4 weeks prior to initiation of study treatment. * Has a history of\nautoimmune disease. * Has a history of hypertension that not well controlled by antihypertensive\ntreatment * Has a history of myocardial infarction, severe/unstable angina pectoris, NYHA Class 2 or\nabove cardiac insufficiency, clinically significant supraventricular or ventricular arrhythmia, or\nsymptomatic congestive heart failure within the last 6 months. * Has a history of (non-infectious)\npneumonitis, interstitial lung disease or uncontrollable systematicness diseases. * Administration\nof a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation\nof need for such a vaccine during the study. * Has a known history of Human Immunodeficiency Virus\n(HIV). * Has known active Hepatitis B, Hepatitis C or Autoimmune hepatitis. * Severe infections\nwithin 4 weeks prior to initiation of study treatment, including but not limited to hospitalization\nfor complications of infection, bacteremia, or severe pneumonia. * Has active infection (CTCAE≥2)\nneeded the treatment of antibiotic within 2 weeks prior to initiation of study treatment. * Has\nevidence of active tuberculosis within 1 year prior to initiation of study treatment. * Prior\nallogeneic stem cell or solid organ transplantation. * Peripheral neuropathy grade ≥2. * Has\nclinically significant intestinal obstruction. * Arterial/venous thrombosis events that occurred\nwithin 3 months before enrollment, such as cerebrovascular accidents, deep vein thrombosis, or\npulmonary embolism. * Has hemoptysis symptoms within 2 months before enrollment and the maximum\ndaily hemoptysis ≥ 2.5 ml. * Clinically significant bleeding symptoms or clear bleeding tendency\noccurred within 3 months before enrollment. * Has known genetic or acquired bleeding or thrombotic\ntendency. * Abnormal coagulation (INR\\>1.5 or APTT\\>1.5 x ULN) with bleeding tendency, receiving\nthrombolysis or anticoagulation therapy, or requiring long-term antiplatelet therapy. * Has a known\nhypersensitivity to the components of the study treatment or other hypersensitivity reactions to\nchimeric or humanized antibodies or fusion proteins. * Female patients during pregnancy and\nlactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are\nunwilling to take effective contraceptive measures throughout the trial. * History of neurological\nor psychiatric disorders, including epilepsy or dementia. * Any other situation evaluated by\nresearchers.",
                    "Interventions Description": "Intravenous (IV) infusion, po., IV infusion., IV infusion., IV infusion.",
                    "NCT ID": "NCT05447702",
                    "Official Title": "A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)"
                }
            },
            {
                "patient_match_result": {
                    "reasoning": "The patient's case and the clinical trial both involve triple-negative breast cancer, which is a positive match. The patient's age, 60, falls within the trial's age range of 18-75 years. The patient's ECOG score of 1 is within the trial's requirement of ≤ 1, indicating that she is physically capable of participating in the trial. The patient's blood test results, including Hemoglobin, Neutrophil count, Platelet count, Total Bilirubin, Alanine aminotransferase, Aspartate aminotransferase, and Serum creatinine, all fall within the acceptable ranges for the trial. \n\nThe patient's tumor is triple-negative, as required by the trial, and she has at least one measurable lesion, which is also a requirement. The patient has not previously been treated with PD-1/PD-L1 antibody, CTLA-4 antibody, or anti-vascular targeted therapy, which is important because the trial excludes patients with a treatment history of PD-1 / PD-L1 inhibitors. \n\nThe patient does not have any of the exclusion criteria listed in the trial, such as central nervous system metastases with clinical symptoms, peripheral neuropathy ≥ grade 2, cardiac dysfunction, hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis and tuberculosis, autoimmune diseases requiring systemic treatment, and a history of pneumonia (requiring corticosteroid treatment) or interstitial lung disease. \n\nThe patient is not pregnant or lactating, and she has not participated in any other clinical trials of drugs in the first four weeks before the first dose. She does not have any history of autoimmune disease or any use of systemic glucocorticoid or immunosuppressive medications. She does not have any hereditary or acquired bleeding and thrombotic tendencies, congenital or acquired immune deficiency, or any other diseases that are unfit for the treatment.\n\n",
                    "answer": "Yes"
                },
                "metadata": {
                    "Brief Summary": "To evaluate the efficacy of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer.",
                    "Brief Title": "Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer",
                    "Conditions": "TNBC - Triple-Negative Breast Cancer",
                    "Eligibility": "Eligibility Criteria:\nHealthy Volunteers: False\nSex: FEMALE\nMinimum Age: 18 Years\nMaximum Age: 75 Years\nStandard Ages: ['ADULT', 'OLDER_ADULT']\nInclusion Criteria:  1. The patients sign the written informed consent. 2. Women aged 18-75. 3. The\npathologic diagnosis of unresectable recurrent or metastatic triple-negative breast cancer ［ER-\nnegative(IHC\\<1%), PR-negative(IHC\\<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］. Patients\nwith at least one measuring lesion that was conformed to RECIST v1.1 standard. 4. PD-1/PD-L1positive\nor TMB≥5. 5. Prior therapy (adjuvant/neoadjuvant/advanced) must have included an anthracycline\nand/or a taxane in any combination or order and either in the early or metastatic disease setting\nunless contraindicated for a given patient. 6. Eastern Cooperative Oncology Group (ECOG) performance\nstatus of ≤ 1. 7. The results of patient's blood tests are as follows:     • Hb≥90g/L; •\nPlt≥100\\^9/L; • Serum albumin ≥3g/dL;• Neutrophils≥1.5\\^9/L; TSH≤ normal upper limit (ULN);• ALT and\nAST ≤1.5 ULN (liver metastases ≤3 ULN); • TBIL ≤ULN (total bilirubin ≤1.5 ULN in Gilbert's syndrome\nor liver metastasis subjects);• ALT and AST ≤1.5 ULN (liver metastases ≤3 ULN);• AKP≤ 2.5 ULN; •\nRenal function within 7 days before the first administration: serum creatinine ≤1.5 ULN or\ncreatinine clearance ≥60mL/min 8. Female subjects of childbearing potential must have a negative\nserum pregnancy test within 7 days before the first dose and must be willing to use very efficient\nbarrier methods of contraception for the course of the study through 6 months after the last dose of\nstudy treatment.  Exclusion Criteria:  1. The subjects had a central nervous system metastases with\nclinical symptoms. 2. Subjects with treatment history of PD-1 / PD-L1 inhibitors; 3. Peripheral\nneuropathy ≥ grade 2; Cardiac dysfunction, hyperthyroidism or hypothyroidism, type 1 diabetes,\nactive hepatitis and tuberculosis; Autoimmune diseases requiring systemic treatment, and a history\nof pneumonia (requiring corticosteroid treatment) or interstitial lung disease. 4. Pregnant or\nlactating women. 5. Other clinical trials of drugs were used in the first four weeks before the\nfirst dose. 6. The subjects had any history of autoimmune disease or any use of systemic\nglucocorticoid or immunosuppressive medications. 7. Hereditary or acquired bleeding and thrombotic\ntendencies (such as hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism, etc.). 8.\nCongenital or acquired immune deficiency (such as HIV infection); 9. Receive live vaccine within 4\nweeks before or during the study period; 10. Patients who are allergic to or contraindicated to the\nexperimental drugs. 11. Other malignant tumors in the past, except cervical cancer and non melanoma\nskin cancer, which have survived for 5 years without disease. 12. Subjects with any other diseases\nthat are unfit for the treatment.",
                    "Interventions Description": "Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle, Sintilimab Injection，Intravenous infusion，200mg，3-week cycle",
                    "NCT ID": "NCT05402722",
                    "Official Title": "A Phase II Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer"
                }
            }
        ]
    }
}